Business Description
Aptevo Therapeutics Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
AP8N.Germany0HH3.UKAPVO.USA Description
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.18 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.64 | |||||
| Debt-to-EBITDA | -0.42 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -7.05 | |||||
| Beneish M-Score | -4.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -43.3 | |||||
| 3-Year EBITDA Growth Rate | 48 | |||||
| 3-Year EPS without NRI Growth Rate | 42.8 | |||||
| 3-Year FCF Growth Rate | 47.3 | |||||
| 3-Year Book Growth Rate | -76.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.55 | |||||
| 9-Day RSI | 34.49 | |||||
| 14-Day RSI | 39.24 | |||||
| 6-1 Month Momentum % | -42.61 | |||||
| 12-1 Month Momentum % | -59.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.16 | |||||
| Quick Ratio | 3.16 | |||||
| Cash Ratio | 2.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -368.74 | |||||
| Net Margin % | 94.36 | |||||
| ROE % | 77.2 | |||||
| ROA % | 13.54 | |||||
| ROIC % | -108.34 | |||||
| ROC (Joel Greenblatt) % | -475.79 | |||||
| ROCE % | -95.77 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1.7 | |||||
| PE Ratio without NRI | 1.95 | |||||
| Price-to-Owner-Earnings | 1.03 | |||||
| PEG Ratio | 0.05 | |||||
| PS Ratio | 1.55 | |||||
| PB Ratio | 0.69 | |||||
| Price-to-Tangible-Book | 0.69 | |||||
| EV-to-EBIT | 0.04 | |||||
| EV-to-EBITDA | 0.05 | |||||
| EV-to-Revenue | -0.16 | |||||
| EV-to-Forward-Revenue | 0.07 | |||||
| EV-to-FCF | 0.06 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.08 | |||||
| Price-to-Graham-Number | 0.24 | |||||
| Price-to-Net-Current-Asset-Value | 1.25 | |||||
| Price-to-Net-Cash | 1.75 | |||||
| Earnings Yield (Greenblatt) % | 2500 |
